China Universal Asset Management Company’s Aclaris Therapeutics ACRS Stock Holding History

China Universal Asset Management Company’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Buy	22,228 +827	+4%	+$3.69K	0.01%	400
2026 Q1	$80.3K	Buy	21,401 +3,746	+21%	+$12.6K	0.01%	425
2025 Q4	$53.1K	Buy	+17,655	New	+$44.6K	﹤0.01%	445
2024 Q4	–	Sell	-13,722	Closed	-$15.8K	–	497
2024 Q3	$15.8K	Buy	13,722 +5,350	+64%	+$6.56K	﹤0.01%	412
2024 Q2	$9.21K	Sell	8,372 -5,255	-39%	-$6.17K	﹤0.01%	400
2024 Q1	$16.9K	Buy	13,627 +5,431	+66%	+$6.48K	﹤0.01%	429
2023 Q4	$8.61K	Buy	8,196 +6,382	+352%	+$19.5K	﹤0.01%	416
2023 Q3	$12.4K	Buy	1,814 +888	+96%	+$7.59K	﹤0.01%	335
2023 Q2	$9.6K	Buy	926 +23	+3%	+$208	﹤0.01%	321
2023 Q1	$7.3K	Buy	903 +225	+33%	+$2.86K	﹤0.01%	333
2022 Q4	$10.7K	Buy	678 +54	+9%	+$869	﹤0.01%	222
2022 Q3	$10K	Buy	+624	New	+$9.83K	﹤0.01%	201

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

TBWA

Three Bridge Wealth Advisors Los Altos, California $399M AUM 18.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

China Universal Asset Management Company's ACRS Position: Q2 2026 in Review

China Universal Asset Management Company increased its Aclaris Therapeutics (ACRS) stake by 3.9% in Q2 2026, buying an estimated $3.69K and bringing the position to 22,228 shares worth $118K. The position accounts for 0.01% of the portfolio, ranked #400.

China Universal Asset Management Company first reported a position in ACRS in Q3 2022 and has held it in 12 quarters since. 74 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

China Universal Asset Management Company held 22,228 shares of Aclaris Therapeutics worth $118K as of Q2 2026.
China Universal Asset Management Company bought 827 Aclaris Therapeutics shares in Q2 2026, an estimated $3.69K.
Aclaris Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #400 holding.
China Universal Asset Management Company first reported a position in Aclaris Therapeutics in Q3 2022 and has held it in 12 quarters since.
74 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.